This review explains how synthetic long peptide vaccines targeting neoantigens — unique mutations found only in a patient's tumor — represent a promising new approach to personalized cancer immunotherapy.
Both CD4+ and CD8+ T cells activatedLong peptide format activates both helper and killer T cells — a key advantage over short peptides that typically only activate CD8+ cells
What the researchers found
Synthetic long peptide (SLP) neoantigen vaccines offer several advantages over traditional short peptide vaccines: they overcome immune tolerance, activate both CD4+ helper and CD8+ killer T cell responses, and target mutations unique to individual tumors rather than shared antigens.
The review summarizes evidence that extending short peptides (8-10 amino acids) into longer formats (25-35 amino acids) improves antigen processing by professional antigen-presenting cells and generates more robust and durable immune responses. Multiple preclinical and early clinical studies have shown encouraging results with personalized neoantigen peptide vaccines.
Why it matters
Cancer immunotherapy has been revolutionized by checkpoint inhibitors, but many patients don't respond. Personalized neoantigen vaccines could complement these treatments by training the immune system to recognize each patient's specific tumor mutations. Long peptide formats are emerging as the preferred delivery platform because they generate broader, more durable immune responses than short peptides — and synthetic peptides are faster and cheaper to manufacture than other vaccine formats.
How the study worked
This is a narrative review published in Theranostics that synthesizes the history of peptide-based cancer vaccines, the scientific rationale for using long peptides over short peptides, the advantages of neoantigen targeting, and current preclinical and clinical developments in the field.
What this study cannot tell us
As a review, no new data is presented. The field is still early-stage — most clinical trials are small, single-arm studies without randomized comparisons. Manufacturing personalized vaccines is time-consuming and expensive. Not all predicted neoantigens generate meaningful immune responses. Tumors can evolve to lose the targeted mutations (immune escape). The optimal adjuvant, dosing schedule, and combination strategies remain undefined.
How to read the evidence
This is a review article summarizing the field of personalized neoantigen peptide vaccines. While it draws on preclinical and early clinical data, no new primary data is presented. The evidence for neoantigen vaccine efficacy is still emerging from early-phase clinical trials.
When this study was published
Published in 2020, this review captures the field at a pivotal moment when several neoantigen vaccine trials were reporting early results. The field has continued to advance rapidly since publication, with larger trials now underway.
The bigger picture
Personalized neoantigen vaccines sit at the intersection of genomics, immunology, and peptide science. As DNA sequencing costs plummet, identifying each patient's unique tumor mutations has become routine. The challenge is turning that genomic data into effective vaccines fast enough to treat patients. Synthetic long peptides offer a practical manufacturing platform, and when combined with checkpoint inhibitors, may dramatically expand the proportion of cancer patients who benefit from immunotherapy.
Questions still open
- How quickly can personalized neoantigen vaccines be manufactured and delivered to patients with rapidly progressing cancers?
- Do neoantigen peptide vaccines work better in combination with checkpoint inhibitors than either approach alone?
- What proportion of computationally predicted neoantigens actually generate clinically meaningful T cell responses?
Common questions
What are neoantigens and why are they better vaccine targets than shared tumor antigens?
Why are long peptides better than short peptides for cancer vaccines?
Read the original research
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Theranostics, 10(13), 6011-6023
Citation
Chen, Xiaotong; Yang, Ju; Wang, Lifeng; Liu, Baorui. (2020). Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.. Theranostics, 10(13), 6011-6023. https://doi.org/10.7150/thno.38742